德福韦酯与拉米夫定联合治疗代偿期乙型肝炎肝硬化的影响研究

摘要

Objective:To investigate the adefovir dipivoxil combined with lamivudine treatment for decompensated cirrhosis of hepatitis curative ef ect.Method:Choose compensatory period of 60 patients with hepatitis b cirrhosis serum HBV DNA positive,were randomly divided into observation group and control group,30 cases each. Observation group was given lamivudine and adefovir combination therapy,the control group given adefovir ester treatment,observe the two groups before treatment and 12, 24 and 48 weeks after treatment of liver function and HBV DNA ration.Result:At 8 weeks ALT recovery rate of observation group was obviously higher than that of control group,two groups compare difference was statistically significant (P<0.05);Serum HBV-DNA replication improvement group was significantly better than control group, two groups of comparisons difference was statistically significant (P<0.05).Conclusion:Lamivudine and adefovir combination therapy compensatory phase of hepatitis b cirrhosis of the liver can effectively inhibit HBV replication and obvious control disease progression and improve prognosis,is worthy of reference for clinical.%　　目的：探讨阿德福韦酯与拉米夫定联合治疗代偿期乙型肝炎肝硬化的疗效。方法：选择代偿期乙肝肝硬化血清HBV DNA阳性患者60例，随机分为观察组和对照组，各30例。观察组给予阿德福韦酯与拉米夫定联合治疗，对照组给予阿德福韦酯治疗，观察两组治疗前及治疗后的12、24、48周肝功能和HBV DNA定量。结果：48周时观察组ALT恢复率明显高于对照组，两组比较差异有统计学意义(P<0.05)；血清HBV-DNA复制改善情况观察组显著优于对照组，两组比较差异有统计学意义(P<0.05)。结论：阿德福韦酯与拉米夫定联合治疗代偿期乙型肝炎肝硬化可有效抑制乙肝病毒复制、明显控制病情进展和改善预后，值得临床借鉴。